|
Lymphoma, Follicular
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Several EZH2 inhibitors, which inhibit the methyltransferase activity of EZH2, have shown promise in treating sarcoma and follicular lymphoma in clinics.
|
31819273 |
2020 |
|
Lymphoma, Follicular
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL) with genetic alterations of BCL-2, KMT2B, and KMT6.
|
30693983 |
2019 |
|
Lymphoma, Follicular
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Early data from the tazemetostat trials indicate an acceptable safety profile and early signs of activity in diffuse large B-cell lymphoma and follicular lymphoma, including patients with EZH2 wild-type and mutant tumors.
|
29473431 |
2018 |
|
Lymphoma, Follicular
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genetic and epigenetic inactivation of <i>SESTRIN1</i> controls mTORC1 and response to EZH2 inhibition in follicular lymphoma.
|
28659443 |
2017 |
|
Lymphoma, Follicular
|
0.600 |
Biomarker
|
disease |
BEFREE |
We evaluated the role of EZH2 genomic gains in FL biology.
|
28430172 |
2017 |
|
Lymphoma, Follicular
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Recurrent mutations of histone modifiers KMT2D, CREBBP, EP300, EZH2, ARIDIA, and linker histones are likely early events arising in the CPC pool, rendering epigenetic based therapies conceptually attractive for treatment of indolent and transformed FL.
|
28106467 |
2017 |
|
Lymphoma, Follicular
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.
|
28411252 |
2017 |
|
Lymphoma, Follicular
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Prioritized alterations in epigenetic modulators were common and included gain-of-function EZH2 and loss-of-function ARID1A mutations (14% of diffuse large B-cell lymphomas and 22% of follicular lymphomas contained alterations in each of these two genes).
|
27102345 |
2016 |
|
Lymphoma, Follicular
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recently, point mutations of EZH2 at Tyr641 and Ala677 were identified in diffuse large B cell lymphoma and follicular lymphoma, where they drive H3K27 hypertrimethylation and cancer progression.
|
27261606 |
2016 |
|
Lymphoma, Follicular
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In particular, recurrent gain-of-function mutations targeting EZH2 Y641 occur most frequently in follicular lymphoma and aggressive diffuse large B-cell lymphoma and are associated with H3K27me3 hyperactivation, which contributes to lymphoma pathogenesis.
|
24469040 |
2015 |
|
Lymphoma, Follicular
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The histone methyltransferase EZH2 is frequently mutated in germinal center-derived diffuse large B-cell lymphoma and follicular lymphoma.
|
24802772 |
2014 |
|
Lymphoma, Follicular
|
0.600 |
Biomarker
|
disease |
BEFREE |
The histone lysine methyltransferase (MT) Enhancer of Zeste Homolog 2 (EZH2) is considered an oncogenic driver in a subset of germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) and follicular lymphoma due to the presence of recurrent, monoallelic mutations in the EZH2 catalytic domain.
|
25457180 |
2014 |
|
Lymphoma, Follicular
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We observed significant association of EZH2 mutation with low morphologic grade follicular lymphomas (grade 1-2, 23.6% vs. grade 3, 7.7%, χ(2) test, P = 0.02).
|
24634383 |
2014 |
|
Lymphoma, Follicular
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
EZH2, as transcriptional repressor, is mutated in high frequency in Chinese and Western patients with follicular lymphoma and may represent a rational target for GC-derived lymphomas..
|
24857928 |
2014 |
|
Lymphoma, Follicular
|
0.600 |
Biomarker
|
disease |
CTD_human |
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.
|
24362818 |
2014 |
|
Lymphoma, Follicular
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overall, the high incidence of EZH2 mutations in FL and their stability during disease progression makes FL an appropriate disease to evaluate EZH2 targeted therapy.
|
24052547 |
2013 |
|
Lymphoma, Follicular
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Additionally, somatic heterozygous mutations of Y641 and A677 residues within the catalytic SET domain of EZH2 occur in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.
|
23051747 |
2012 |
|
Lymphoma, Follicular
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
EZH2 mutations were frequently associated with the presence of BCL2 rearrangement (BCL2-R) in both the FL (28% of BCL-R cases versus 0% of BCL2-WT cases, p<0.05) and GCB-DLBCL groups (33% of BCL2-R cases versus 4% of BCL2-WT cases, p<0.04), and across all lymphoma types excluding BL (27% of BCL2-R cases versus 3% of BCL2-WT cases, p<0.003).
|
22194861 |
2011 |
|
Lymphoma, Follicular
|
0.600 |
Biomarker
|
disease |
BEFREE |
These mutations, which result in the replacement of a single tyrosine in the SET domain of the EZH2 protein (Tyr641), occur in 21.7% of GCB DLBCLs and 7.2% of FLs and are absent from ABC DLBCLs.
|
20081860 |
2010 |
|
Lymphoma, Follicular
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|